Evidence map›Paper›PMID 42372830›Full record

ArticleThe Journal of allergy and clinical immunology2026

Selective elimination of mast cells via Siglec-6-targeted nanodelivery of drug payload.

Ariel Helms Thames, Clayton H Rische, Rebecca A Krier-Burris, Yun Cao, Andrew C Hunt, Natalie R Klug, Stephanie R Zelenetz, Evan R Burleigh, Rochelle Aw, Derek A Wong and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ariel Helms ThamesMedical Scientist Training Program, Northwestern University, Chicago, Ill; Division of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill; Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, Ill; Center for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Clayton H RischeDivision of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill; Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill; Department of Human Genetics, Biological Sciences Division, University of Chicago, Chicago, Ill.
Rebecca A Krier-BurrisDivision of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill.
Yun CaoDivision of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill.
Andrew C HuntCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Natalie R KlugDepartment of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Stephanie R ZelenetzDepartment of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Evan R BurleighDepartment of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Rochelle AwCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill; Department of Bioengineering, Stanford University, Stanford, Calif.
Derek A WongCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Zachary M ShaverMedical Scientist Training Program, Northwestern University, Chicago, Ill; Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, Ill; Center for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Kosuke SekiCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Laura GuerreroCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill; Department of Bioengineering, Stanford University, Stanford, Calif.
Regina FernandezCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Swagat SharmaDepartment of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill.
Bruce S BochnerDivision of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill.
Michael C JewettCenter for Synthetic Biology, Northwestern University, Evanston, Ill; Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, Ill; Department of Bioengineering, Stanford University, Stanford, Calif.
Evan A ScottDepartment of Biomedical Engineering, NanoSTAR Institute, University of Virginia School of Medicine, Charlottesville, Va.
Jeremy A O'SullivanDivision of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: jeremy.osullivan@northwestern.edu.

Funding

A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bondingR01EB030629 · NIBIB · NORTHWESTERN UNIVERSITY · PI SCOTT, EVAN ALEXANDER · 2021 to 2024
$1.8M
Modulation and exploitation of Siglec-6 function to broadly impede mast cell activationR01AI158697 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Jeremy A O'Sullivan · 2024 to 2026
$1.4M
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cellsR21AI159586 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BOCHNER, BRUCE S, SCOTT, EVAN ALEXANDER · 2021 to 2022
$417k
Combining Bacterial Glycosylation Tools and Nanotechnology to Optimize Siglec Ligands for the Treatment of Allergy and AnaphylaxisF31AI165279 · NIAID · NORTHWESTERN UNIVERSITY · PI THAMES, ARIEL · 2021 to 2023
$70k
Enhancing the immunogenicity of pneumococcal conjugate vaccines through site-specific glycosylation and presentation on synthetic vesiclesF30AI188632 · NIAID · NORTHWESTERN UNIVERSITY · PI SHAVER, ZACHARY MCDONALD · 2025 to 2025
$45k
NIAID NIH HHS F30 AI188632NIAID NIH HHS F31 AI165279NIAID NIH HHS R01 AI158697NIAID NIH HHS R21 AI159586NIBIB NIH HHS R01 EB030629
6 · The paper itself

Abstract

backgroundMast cell elimination through sialic acid immunoglobulin-like lectin 6 (Siglec-6) is a promising, yet minimally explored strategy for diseases characterized by mast cell overactivity or overproduction.

objectiveWe combined nanotechnology with cell-free protein synthesis to develop a therapeutic strategy (anti-Sig6-NPmidoFab) for selectively eliminating mast cells.

methodsNanocarriers are loaded with the protein kinase inhibitor midostaurin and conjugated with cell-free protein synthesis-enabled clickable, synthetically dimerized anti-Siglec-6 antibody fragments to selectively target Siglec-6-expressing mast cells.

resultsUsing human mast cell lines and primary human mast cells as well as a Siglec-6 knock-in mouse model and a humanized mast cell malignancy mouse model, we demonstrated selective elimination of Siglec-6-positive mast cells with reduced off-target effects on Siglec-6-negative cells.

conclusionThis approach offers new treatment strategies for malignant and nonmalignant mast cell-mediated disease with potential for broad application.

Indexed as

cancercell-free protein synthesismast cellsmastocytosisNanotherapySiglec-6

Identifiers

PMID42372830
PMCPMC13390790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.